Thomas Striepe - Sangui Biotech CEO and President and Executive Director

SGBI Stock  USD 0  0.00  0.00%   

CEO

Mr. Thomas Striepe is Chief Executive Officer, Director of Sangui Biotech International Inc. He is Vice President Accounting and Controlling at Treukonzept Finance GmbH, Hamburg, Germany, a financial services company. Prior to joining Treukonezpt Finance GmbH in 2004, he held management positions in the accounting departments of several German and international corporations. He holds an MBA of Hamburg University. since 2008.
Age 61
Tenure 16 years
Professional MarksMBA
Phone49 40 609 3120
Webhttps://www.sanguibiotech.com

Sangui Biotech Management Efficiency

The company has return on total asset (ROA) of (0.6411) % which means that it has lost $0.6411 on every $100 spent on assets. This is way below average. Sangui Biotech's management efficiency ratios could be used to measure how well Sangui Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 48.9 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Sangui Biotech Inter has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Sangui Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Sangui Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sangui Biotech Inter sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sangui to invest in growth at high rates of return. When we think about Sangui Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 12 records

CEO Age

Udit BatraMERCK Kommanditgesellschaft Auf
47
Christophe WeberTakeda Pharmaceutical Co
58
Christophe WeberTakeda Pharmaceutical Co
57
Walter GalinatMERCK Kommanditgesellschaft Auf
61
David DomzalskiVyne Therapeutics
57
Erez VigodmanTeva Pharmaceutical Industries
55
Robert KoremansTeva Pharmaceutical Industries
54
Bernd ReckmannMERCK Kommanditgesellschaft Auf
60
Kaare SchultzTeva Pharmaceutical Industries
58
Sigurdur OlafssonTeva Pharmaceutical Industries
46
Neil SwiftTakeda Pharmaceutical Co
N/A
Carlo NotaristefaniTeva Pharmaceutical Industries
60
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany. Sangui Biotech is traded on OTC Exchange in the United States. Sangui Biotech International [SGBI] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Sangui Biotech Inter Leadership Team

Elected by the shareholders, the Sangui Biotech's board of directors comprises two types of representatives: Sangui Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sangui. The board's role is to monitor Sangui Biotech's management team and ensure that shareholders' interests are well served. Sangui Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sangui Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Hubertus Schmelz, Non-Executive Director
Thomas Striepe, CEO and President and Executive Director

Sangui Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sangui Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sangui Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sangui Biotech's short interest history, or implied volatility extrapolated from Sangui Biotech options trading.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangui Biotech International. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Sangui Biotech Inter information on this page should be used as a complementary analysis to other Sangui Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Sangui Pink Sheet analysis

When running Sangui Biotech's price analysis, check to measure Sangui Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangui Biotech is operating at the current time. Most of Sangui Biotech's value examination focuses on studying past and present price action to predict the probability of Sangui Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangui Biotech's price. Additionally, you may evaluate how the addition of Sangui Biotech to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Please note, there is a significant difference between Sangui Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangui Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangui Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.